Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ocumension Therapeutics
Deal Watch: Novartis Acquires Gene Therapy Candidate From AvroBio
AvroBio retains rights to its other HSC gene therapy candidates. Alimera Acquires Further Commercial Rights To Eyepoint’s Uveitis Drug.
Nicox’s NCX 470 Hits Phase III Endpoint In Glaucoma But Misses Superiority
NCX 470 demonstrates non-inferiority in intraocular pressure reduction versus latanoprost in the first of two Phase III studies, but does not meet a secondary endpoint that would have shown superiority.
Emerging Biopharma’s Next First Launch Market: China?
Despite multiple challenges including pricing pressures and slowing general economic growth, China offers attractive opportunities for emerging biopharma firms, helped by an encouraging regulatory environment. But weighing up options around challenging areas including partnering is essential, a new report states.
Asia Deal Watch: Innovent And Bolt Collaborate On Immune-Stimulating Antibody Conjugates
Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.